Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured approximately 4 billion yuan ($581 million) from its parent firm and a slew of notable investors, according to a filing on the Shenzhen Stock Exchange on Friday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
